Mr. Stephen Kilmer reports

PROFOUND MEDICAL AND COOK MEDICAL'S IMRI DIVISION PARTNER TO EXPAND U.S. TULSA-PRO® SALES CHANNELS AND DRIVE RECURRING REVENUE GROWTH

Profound Medical Corp. has entered into a supply and distribution agreement with the iMRI division of Cook Medical to expand United States sales of its Tulsa-Pro system.

• New distribution agreement positions Tulsa-Pro within the iMRI suite offering through Cook Medical's Copernicus program, expanding Profound's commercial reach.
• Profound retains direct Tulsa-Pro recurring treatment kit and service revenue relationships for systems sold through Cook Medical.
• Agreement complements Profound's existing Siemens Healthineers relationship and broader strategy to expand access to MRI-guided regional prostate ablation.

The iMRI suite, developed by Cook Medical and Siemens Healthineers, is a fully integrated procedural environment that enables real-time MRI-guided interventions without ionizing radiation. It is built for intervention from the ground up. Cook's Copernicus program connects the iMRI suite with designed-for-MRI devices, clinical training, implementation support and partner therapies, giving hospitals a single pathway from planning an iMRI program to treating patients.

The agreement establishes an additional new capital equipment sales channel for Profound by bringing its Tulsa-Pro system into the Copernicus program alongside the iMRI suite, enabling Cook to offer a turnkey prostate disease treatment solution to urologists and hospitals. The collaboration is intended to increase Tulsa-Pro system placements, expand the base of systems generating recurring revenue, and broaden physician and patient access to the Tulsa Procedure.

Expanding commercial reach

Under the agreement, Cook will purchase Tulsa-Pro systems from Profound at a predetermined transfer price for distribution in the United States. Customers purchasing systems through Cook will obtain single-use disposables and service contracts directly from Profound.

Profound's existing capital sales team will continue to sell Tulsa-Pro directly to sites with compatible MRI systems. Together, these channels allow the company to serve customers using existing MRI infrastructure and those investing in new iMRI capabilities.

"This agreement broadens our commercial reach by making Tulsa-Pro part of a comprehensive offering for hospitals investing in MRI-guided intervention," said Arun Menawat, Profound's chief executive officer and chairman. "Cook's expertise in minimally invasive procedures, its large presence in urology and its investment in iMRI complement our direct sales capabilities. Together, we have an opportunity to bring Tulsa to more institutions and build procedure volumes as new sites establish and expand their treatment programs."

"Cook Medical has spent decades helping physicians perform minimally invasive procedures, and our iMRI division is carrying that work into MRI-guided intervention," said Pete Polverini, vice-president, interventional MRI division, at Cook Medical. "Through our Copernicus program we help hospitals plan, build and sustain iMRI programs, and Tulsa-Pro gives those hospitals an FDA-cleared, incision-free prostate therapy to offer patients who want to return to their daily lives sooner. Together with Profound, we aim to bring the Tulsa Procedure to more urologists and more hospitals and, over time, to additional sites of care."

Building a broader iMRI ecosystem

The Cook agreement complements Profound's existing co-sales and co-marketing agreement with Siemens Healthineers to commercialize a total MRI-guided prostate therapy solution combining Tulsa-Pro with Siemens Healthineers' Magnetom Free.Max magnetic resonance scanner.

Separately, Cook Medical and Siemens Healthineers unveiled the radiation-free iMRI suite at the Society of Interventional Radiology's 2026 Annual Scientific Meeting, highlighting the expanding ecosystem of imaging technology, interventional devices and clinical workflows supporting MRI-guided procedures.

Together, these commercial relationships broaden Profound's access to customers across existing MRI installations and new interventional suites, strengthening the foundation for sustained adoption of the Tulsa Procedure.

About Profound Medical Corp.

Profound is a commercial-stage medical device company and an innovator in interventional MRI (iMRI) procedures. The company's flagship platform, Tulsa-Pro, enables MRI-guided, incision-free prostate ablation. Physicians use the Tulsa Procedure to see, ablate and confirm therapy in real time, supporting personalized treatment strategies across the continuum of prostate care -- from whole-gland to subtotal, hemi, multifocal and focal treatment. This approach enables individualized care using prostate tissue ablation, while minimizing the potential of the side effects that are typically associated with surgery or radiation, such as urinary incontinence and/or erectile dysfunction.

Profound also commercializes Sonalleve, an MRI-guided therapy that provides a non-surgical treatment option for pain palliation of bone metastases, desmoid tumours and osteoid osteoma, as well as for common gynecologic conditions including uterine fibroids and adenomyosis. Sonalleve delivers targeted therapy with no incisions, no blood loss during the procedure, no overnight hospital stay and faster recovery -- and, in gynecologic applications, enables uterine-sparing treatment that may help preserve fertility. Profound is also exploring additional clinical applications for Sonalleve, including non-invasive ablation of abdominal cancers and hyperthermia-based cancer therapies.

Profound Medical's technologies are approved across major global markets. Tulsa-Pro is cleared by the Food and Drug Administration in the United States for transurethral ultrasound ablation (Tulsa) of prostate tissue. In addition, Tulsa-Pro is cleared for use in various jurisdictions including Europe, Canada, Saudi Arabia, India, Australia/New Zealand and the United Arab Emirates. Sonalleve is approved by the Food and Drug Administration as HDE in the United States for the treatment of osteoid osteomas in the extremities. Sonalleve is also cleared or approved in Europe, Canada, China and Saudi Arabia.

Through real-time MRI guidance and data-driven innovation, Profound is advancing the future of MRI-guided therapy -- expanding access to precise, personalized and incision-free treatment options worldwide.

We seek Safe Harbor.